Welcome to our dedicated page for Albemarle SEC filings (Ticker: ALB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Albemarle Corporation filings document operating results, material events, governance matters, shareholder voting items, and capital-structure disclosures for a public specialty chemicals and critical materials company. Form 8-K reports cover quarterly financial results, credit agreement amendments, debt-related actions, board appointments, officer transitions, and completed portfolio transactions.
Proxy materials describe director elections, committee governance, executive compensation, shareholder proposals, and voting procedures. Albemarle's filing record also documents the completed disposition of a controlling stake in Ketjen, retained ownership interests, integration of Performance Catalyst Solutions, and financing arrangements tied to the company's global lithium, bromine and specialty product businesses.
Albemarle Corporation filed Amendment No. 1 to its Annual Report for the year ended December 31, 2025 to add separate financial statements for Windfield Holdings Pty Ltd. These Windfield statements are required under Rule 3-09 of Regulation S-X and are provided as Exhibit 99.1.
Windfield was significant under Rule 3-09 for the year ended December 31, 2023, so the amendment includes unaudited consolidated financial statements for 2025 and 2024 and audited consolidated financial statements for 2023. The amendment also refreshes Part IV, Item 15 with related exhibits, including new CEO and CFO certifications and an accountants’ consent, while leaving all other disclosures from the original annual report unchanged.
Albemarle Corp Schedule 13G/A amendment shows The Vanguard Group reporting zero beneficial ownership of Common Stock after an internal realignment. The filing states certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is dated 03/13/2026 and signed on 03/26/2026 by Ashley Grim, Head of Global Fund Administration.
Albemarle Corporation entered into a third amendment to its amended and restated credit agreement on March 19, 2026. The amendment extends the facility’s maturity date to at least October 28, 2028, with a possible one-year extension under specified conditions.
The changes also remove a 0.10% interest rate adjustment applied to SOFR-based loans and limit Albemarle’s ability to request maturity extensions from two times to one. Overall, the update reshapes key terms of the company’s core bank credit facility without changing lenders or the administrative agent.
Albemarle Corporation has issued its 2026 proxy statement, pairing a review of 2025 performance with proposals for shareholder votes at the May 5, 2026 annual meeting. In 2025 the company generated $5.1 billion in net sales and $1.3 billion in operating cash flow, reflecting an 86% increase driven by cost reductions, productivity gains, working capital actions, and a customer prepayment. Management reports about $450 million in cost and productivity improvements and portfolio moves including divesting its Refining Solutions controlling interest and a 50% Eurecat stake, with approximately $670 million of pre-tax proceeds received in March 2026. Shareholders are asked to elect ten directors, approve an advisory say-on-pay vote, ratify PwC as auditor, remove remaining supermajority voting provisions from the charter, approve a new 2026 equity incentive plan, and consider a shareholder proposal to allow 10% holders to call special meetings, which the board opposes.
Albemarle Corporation files an automatic shelf registration on Form S-3 as a "well-known seasoned issuer," establishing a prospectus that permits the company to offer, from time to time after the effective date, common stock, preferred stock, debt securities, warrants, depositary shares and units.
The prospectus describes authorized shares, corporate governance and anti-takeover provisions, use of proceeds for general corporate purposes, and detailed mechanics for debt securities, including covenants, defeasance, and events of default. Specific offering terms will be provided in prospectus supplements.
Albemarle Corporation files an automatic shelf registration on Form S-3 as a "well-known seasoned issuer," establishing a prospectus that permits the company to offer, from time to time after the effective date, common stock, preferred stock, debt securities, warrants, depositary shares and units.
The prospectus describes authorized shares, corporate governance and anti-takeover provisions, use of proceeds for general corporate purposes, and detailed mechanics for debt securities, including covenants, defeasance, and events of default. Specific offering terms will be provided in prospectus supplements.
Albemarle Corporation Chairman & CEO J. Kent Masters reported both stock sales and a gift of shares. On March 10, 2026, he sold a total of 11,783 shares of Albemarle common stock in open-market transactions at weighted-average prices with ranges from $169.63 to $171.89 per share for diversification and tax planning purposes. After these sales, he directly held 134,628 shares.
On March 12, 2026, he made a bona fide gift of 30,716 shares, transferring them to an irrevocable trust over which he has no influence or control. Following this transfer, he directly holds 103,912 shares, which the disclosure notes remain in excess of his required holdings under Albemarle’s stock ownership guidelines.
Albemarle Corporation requests shareholder votes at its May 5, 2026 Annual Meeting and presents its 2026 proxy and 2025 Annual Report. The company reports $5.1 billion in 2025 net sales and $1.1 billion adjusted EBITDA, with 7% volume growth and $1.3 billion operating cash flow (an 86% increase year-over-year). The proxy includes management proposals to elect ten directors, ratify PwC as auditor, remove remaining supermajority charter provisions, and approve the 2026 Incentive Plan. The Board added two independent directors and discloses proceeds from strategic portfolio actions, including a $350 million customer prepayment, a $307.4 million redemption, and combined pre-tax divestiture proceeds of approximately $670 million received at close in March 2026. Voting is for shareholders of record as of March 11, 2026.
ALBEMARLE CORP director Alejandro Daniel Wolff increased his stake through automatic dividend reinvestment. On January 2, 2026, he acquired 32 shares of common stock at a stated price of $0.00 per share, bringing his directly held position to 12,986 shares.
The Form 4 also reports earlier dividend reinvestment acquisitions of 46 shares on October 1, 2024, 42 shares on July 1, 2024, 32 shares on April 2, 2024, 29 shares on January 3, 2024, and 25 shares on October 3, 2023. All transactions are described as dividends acquired under an automatic dividend reinvestment program, indicating routine, compensation-like share accumulations rather than open‑market purchases.
Albemarle Corporation reported a Form 144 notice to sell 11,783 shares. The filing lists Goldman Sachs & Co. LLC as the broker and an aggregate amount of $1,962,340.82. The securities were acquired as compensation (Restricted Stock Units) on 02/26/2026, 02/18/2022, and 05/05/2023, with per‑lot quantities of 5,108, 3,568, and 3,107 shares respectively.